NO20090788L - Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase - Google Patents
Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinaseInfo
- Publication number
- NO20090788L NO20090788L NO20090788A NO20090788A NO20090788L NO 20090788 L NO20090788 L NO 20090788L NO 20090788 A NO20090788 A NO 20090788A NO 20090788 A NO20090788 A NO 20090788A NO 20090788 L NO20090788 L NO 20090788L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- tyrosine kinase
- ret
- receptor tyrosine
- ret receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84276606P | 2006-09-07 | 2006-09-07 | |
| PCT/GB2007/003335 WO2008029123A1 (en) | 2006-09-07 | 2007-09-06 | Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20090788L true NO20090788L (no) | 2009-03-13 |
Family
ID=38829617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090788A NO20090788L (no) | 2006-09-07 | 2009-02-19 | Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110028498A1 (ko) |
| EP (1) | EP2064340A1 (ko) |
| JP (1) | JP2010502209A (ko) |
| KR (1) | KR20090048644A (ko) |
| CN (1) | CN101512017A (ko) |
| AU (1) | AU2007293280A1 (ko) |
| BR (1) | BRPI0716555A2 (ko) |
| CA (1) | CA2662591A1 (ko) |
| IL (1) | IL197157A0 (ko) |
| MX (1) | MX2009002471A (ko) |
| NO (1) | NO20090788L (ko) |
| WO (1) | WO2008029123A1 (ko) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802384B2 (en) * | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| EP2714937B1 (en) * | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CN103930571A (zh) * | 2011-11-17 | 2014-07-16 | 瑞尼克斯有限公司 | 用于选择性分子分析的系统和方法 |
| WO2013172961A1 (en) * | 2012-05-14 | 2013-11-21 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| CA3009552A1 (en) * | 2013-03-15 | 2014-09-18 | Expression Pathology, Inc. | Srm assay to indicate cancer therapy |
| JP6411379B2 (ja) | 2013-05-14 | 2018-10-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー |
| JP6130755B2 (ja) * | 2013-08-12 | 2017-05-17 | ルネサスエレクトロニクス株式会社 | 半導体装置およびその製造方法 |
| ES2926687T3 (es) | 2014-08-28 | 2022-10-27 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y método para su producción |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| WO2017134115A1 (en) * | 2016-02-01 | 2017-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for determining responsiveness to vandetanib in a patient suffering from medullary thyroid carcinoma |
| CN110446790B (zh) * | 2016-11-30 | 2023-03-31 | 外来体诊断公司 | 使用外来体rna和无细胞dna检测血浆中的突变的方法和组合物 |
| CN109439752B (zh) * | 2018-11-16 | 2022-02-15 | 上海派森诺医学检验所有限公司 | 一种鉴别甲状腺髓样癌ret基因突变的特异性引物组合及其试剂盒及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| ITMI20021620A1 (it) * | 2002-07-23 | 2004-01-23 | Novuspharma Spa | Composto ad ativita' antitumorale |
-
2007
- 2007-09-06 CA CA002662591A patent/CA2662591A1/en not_active Abandoned
- 2007-09-06 MX MX2009002471A patent/MX2009002471A/es not_active Application Discontinuation
- 2007-09-06 KR KR1020097006399A patent/KR20090048644A/ko not_active Application Discontinuation
- 2007-09-06 US US12/438,306 patent/US20110028498A1/en not_active Abandoned
- 2007-09-06 CN CNA2007800330353A patent/CN101512017A/zh active Pending
- 2007-09-06 WO PCT/GB2007/003335 patent/WO2008029123A1/en active Application Filing
- 2007-09-06 AU AU2007293280A patent/AU2007293280A1/en not_active Abandoned
- 2007-09-06 JP JP2009527195A patent/JP2010502209A/ja active Pending
- 2007-09-06 EP EP07804140A patent/EP2064340A1/en not_active Withdrawn
- 2007-09-06 BR BRPI0716555-2A2A patent/BRPI0716555A2/pt not_active IP Right Cessation
-
2009
- 2009-02-19 IL IL197157A patent/IL197157A0/en unknown
- 2009-02-19 NO NO20090788A patent/NO20090788L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0716555A2 (pt) | 2013-09-24 |
| EP2064340A1 (en) | 2009-06-03 |
| AU2007293280A1 (en) | 2008-03-13 |
| IL197157A0 (en) | 2009-11-18 |
| KR20090048644A (ko) | 2009-05-14 |
| CN101512017A (zh) | 2009-08-19 |
| WO2008029123A1 (en) | 2008-03-13 |
| US20110028498A1 (en) | 2011-02-03 |
| CA2662591A1 (en) | 2008-03-13 |
| JP2010502209A (ja) | 2010-01-28 |
| MX2009002471A (es) | 2009-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090788L (no) | Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase | |
| Kario et al. | 2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network | |
| ES2422735T3 (es) | Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502 | |
| WO2012106514A3 (en) | System and method for diagnosis and treatment | |
| WO2008083238A3 (en) | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | |
| BRPI0908026B8 (pt) | uso de rifaximina no tratamento de doenças do intestino | |
| BRPI0507442B8 (pt) | método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia | |
| Verdecchia et al. | Home blood pressure measurements will not replace 24-hour ambulatory blood pressure monitoring | |
| EA201170504A1 (ru) | Арильные агонисты рецептора gpr120 и их применение | |
| WO2014015149A3 (en) | Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions | |
| NO20070521L (no) | Fremgangsmater relatert til en enkel nukleotid polymorfisme av den G-proteinkoplede reseptor, GPR40 | |
| DK1915620T3 (da) | Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer | |
| WO2010120942A3 (en) | Histone modification patterns for clinical diagnosis and prognosis of cancer | |
| WO2010041149A3 (en) | Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis | |
| WO2012009382A3 (en) | Molecular indicators of bladder cancer prognosis and prediction of treatment response | |
| WO2010028373A3 (en) | Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients | |
| Dietz et al. | Aspergillus fumigatus induction of IL‐33 expression in chronic rhinosinusitis is PAR2‐dependent | |
| WO2006046270A3 (en) | Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof | |
| NO330943B1 (no) | En metode for detektering og/eller typebestemmelse og/eller kvantifisering av human papillomavirus (HPV) type, primere og prober derav samt diagnostisk sett og anvendelse derav. | |
| WO2009004914A1 (ja) | フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ | |
| ATE529750T1 (de) | Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target | |
| WO2017167942A8 (en) | Method for predicting the response of melanoma patients to a medicament | |
| WO2007085958A3 (en) | Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker | |
| WO2010148323A3 (en) | Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus-related virus | |
| DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |